ACUT (Accustem Sciences) Net Income From Continuing Operations: $-1.65 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACUT Accustem Sciences Inc ACUT
29 GF Score
Price $0.18
View Full Analysis

What is Accustem Sciences Net Income From Continuing Operations?

Accustem Sciences ACUT +12.97% 29 Net Income From Continuing Operations is $-1.65 Mil as of Jun. 2026. GuruFocus rates ACUT with a GF Score™ of 29/100.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Accustem Sciences's net income from continuing operations for the three months ended in Jun. 2026 was $-0.25 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.65 Mil.

Accustem Sciences Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Accustem Sciences's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accustem Sciences Net Income From Continuing Operations Chart

Accustem Sciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Net Income From Continuing Operations
-3.75 -2.05 -1.51 -1.76

Accustem Sciences Quarterly Data
Jun21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.40 -0.51 -0.49 -0.25
ACUT
29GF Score
Accustem Sciences Inc ACUT
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accustem Sciences Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $-1.65 Mil mean?
Accustem Sciences (ACUT) has a Net Income From Continuing Operations of $-1.65 Mil as of Jun. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Accustem Sciences and its competitors.
Is Accustem Sciences' Net Income From Continuing Operations too high?
Accustem Sciences' current Net Income From Continuing Operations is $-1.65 Mil. Overall, Accustem Sciences has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Accustem Sciences' Net Income From Continuing Operations compare to BIXT and CMND?
Accustem Sciences' Net Income From Continuing Operations of $-1.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Accustem Sciences and its competitors. Accustem Sciences's current Net Income From Continuing Operations is $-1.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accustem Sciences stock overvalued right now?
Accustem Sciences (ACUT) has a current Net Income From Continuing Operations of $-1.65 Mil. The current Net Income From Continuing Operations is $-1.65 Mil. Accustem Sciences' overall GF Score™ is 29/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Accustem Sciences (ACUT), the current Net Income From Continuing Operations is $-1.65 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accustem Sciences Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10001
Accustem Sciences Inc is a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people who are diagnosed with cancer each year. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services.
29GF Score

Get the complete analysis for ACUT

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price